Navigation Links
Financial Results for Full Year 2008: NicOx in a Unique Position to Deliver Significant Shareholder Value
Date:2/26/2009

ew nitric oxide-donating antihypertensive drugs and is testing a number of compounds with single and multiple ascending dosing, prior to the selection of a candidate to be advanced into phase 2. The main objectives of these studies are to assess the efficacy, safety, tolerability and pharmacokinetics of these compounds.

Ophthalmology agreements with Pfizer Inc

NicOx and Pfizer are currently in discussions regarding the rights to PF-03187207 for glaucoma (PF-03187207 is covered by the companies' August 2004 agreement). This follows the results of two phase 2 studies in the US and Japan, which demonstrated an improvement over Xalatan(R) 0.005% that did not reach statistical significance on the primary endpoint. The March 2006 agreement granted Pfizer the exclusive right to apply NicOx' nitric oxide-donating technology across the entire field of ophthalmology and current research activities are focused on compounds for the potential treatment of diabetic retinopathy.

Results of a phase 2 study for TPI 1020 in COPD

In December, NicOx and its partner Topigen Pharmaceuticals Inc. announced the results of a phase 2 study for TPI 1020 in patients with Chronic Obstructive Pulmonary Disease (COPD). TPI 1020 did not obtain the differentiated activity required to be advanced into further development in this indication. Topigen and NicOx are currently exploring other possible therapeutic opportunities for TPI 1020 in the respiratory field.

Financial consolidated results on December 31, 2008 and 2007:

Revenues

NicOx' revenues totaled EUR3.4 million in 2008, compared to EUR20.6 million in 2007. This significant decrease is explained principally by the fact that the Company received EUR10.0 million from Merck and EUR1.0 million from Pfizer in 2007, which were entirely recognized as revenues in 2007.

    In 2008, NicOx recognized the following amounts i
'/>"/>
SOURCE NicOx
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15

Related biology technology :

1. Arpida Announces Full Year 2008 Financial Results
2. Nektar Therapeutics Reports Fourth Quarter and Year-End 2008 Financial Results
3. ViroPharma Incorporated Reports Fourth Quarter and Full Year 2008 Financial Results
4. American Oriental Bioengineering, Inc. to Report Fourth Quarter and Full Year 2008 Financial Results on March 9, 2009
5. Frontage Laboratories Continues to Grow Its China Business and Add Corporate Financial, Regulatory and Clinical Pharmacology Talent
6. InterMune to Release Fourth Quarter, Full Year 2008 Financial Results on February 26
7. CV Therapeutics Reports 2008 Fourth Quarter and Full Year Financial Results
8. Human Genome Sciences to Sponsor Conference Call to Discuss Full Year 2008 Financial Results
9. Adolor Corporation to Host Investor Conference Call to Report 2008 Financials and Provide an Update on the Launch of ENTEREG(R) (alvimopan)
10. BioMarin Announces Fourth Quarter and Full Year 2008 Financial Results
11. Senesco Technologies Reports Second Quarter Fiscal 2009 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... , Dec. 23, 2014 China Biologic ... "Company"), a leading fully integrated plasma-based biopharmaceutical company ... that its majority-owned subsidiary, Shandong Taibang Biological Products ... certification from the China Food and Drug Administration ... facility. As previously disclosed in the Company,s public ...
(Date:12/24/2014)... and NEW YORK , Dec. 23, ... open-label pilot study of mazindol in children with attention ... Therapy in December 2014 . The ... children with attention deficit/hyperactivity disorder" ( Konofal et al, ... Dec 1;8:2321-2332. eCollection 2014 ) shows that mazindol ...
(Date:12/22/2014)... GenomeDx Biosciences today announced that a new ... genomic test for prostate cancer, was able to predict ... radical prostatectomy without adjuvant therapy. Although rapid metastasis in ... tumor genomics to identify these men who have a ... advance. The study has been published online by ...
(Date:12/19/2014)... (PRWEB) December 19, 2014 Bioject ... developer and manufacturer of needle-free injection technology, today ... with Immunomic Therapeutics, Inc. (“ITI”) for ITI to ... with its LAMP™ vaccine platform. , In ... exclusive Worldwide license to the Biojector®-2000 that triggers ...
Breaking Biology Technology:China Biologic Receives GMP Certification for New Coagulation Factor Facility 2China Biologic Receives GMP Certification for New Coagulation Factor Facility 3Redefining ADHD: A New Approach & A Shift of Paradigm in ADHD Therapeutics 2Redefining ADHD: A New Approach & A Shift of Paradigm in ADHD Therapeutics 3Study Published in European Urology Shows that the Decipher Prostate Cancer Classifier is Predictive of Rapid Metastasis in High-Risk Men who have had Prostate Surgery 2Study Published in European Urology Shows that the Decipher Prostate Cancer Classifier is Predictive of Rapid Metastasis in High-Risk Men who have had Prostate Surgery 3Bioject and Immunomic Therapeutics Enter into an Agreement for License of Needle-Free Technology for LAMP-vax Vaccines 2Bioject and Immunomic Therapeutics Enter into an Agreement for License of Needle-Free Technology for LAMP-vax Vaccines 3
... America,s war on terror includes fighting the dark ... chemist Dr. Frank Raushel is helping with the fight ... chemical agent, the organophosphates. , Synthetic organophosphates started their ... their way into the dangerous alleys of chemical warfare ...
... away, but soccer aficionados can get an early start ... National Institute of Standards and Technology (NIST) and the ... summer. , Nanosoccerthe Lilliputian competition where computer-driven "nanobots" the ... no bigger than a grain of ricewill be part ...
... SAN DIEGO, Nov. 13 Gen-Probe Incorporated,(Nasdaq: GPRO ... the Lazard,Capital Markets 5th Annual Healthcare Conference on Tuesday, ... presentation is scheduled,to be webcast live and may be ... website at http://www.gen-probe.com . The webcast,will be available ...
Cached Biology Technology:Researcher working on destruction of chemical weapons 2Let the games begin! Nanosoccer at 2009 RoboCup in Austria 2Gen-Probe to Webcast Presentation at the Lazard Capital Markets 5th Annual Healthcare Conference 2
(Date:12/17/2014)... Dec. 15, 2014  HITLAB SM announced ... (GCP) audit to confirm its adherence to current ... accomplishment enables HITLAB to conduct regulated smart device ... principles for patient safety and research quality. ... access, quality, and delivery with innovative technology," said ...
(Date:12/17/2014)... Research and Markets ( http://www.researchandmarkets.com/research/9zq33j/global_chemical ... "Global Chemical Sensor Market 2015-2019" report to ... One major trend upcoming in ... sensors in biomedical applications. Chemical sensors help in ... diagnosis during surgical procedures. The Global Chemical Sensor ...
(Date:12/15/2014)... DUBLIN , Dec. 12, 2014 Research ... announced the addition of the "Global Facial ... http://photos.prnewswire.com/prnh/20130307/600769 ... the identification of individuals. Facial recognition system measures ... as nose, jaw edges, mouth, and the distance ...
Breaking Biology News(10 mins):HITLAB Completes GCP Audit for FDA Smart Device & App Compliance 2Global Chemical Sensor Market 2015-2019: Key Vendors are Abbott Laboratories, Bayer, Hoffmann La-Roche, Johnson & Johnson, NGK Spark Plugs and Robert Bosch 2Global Facial Recognition Market 2015-2019: Key Vendors are 3M Cogent, Cognitec Systems, NEC and Safran Group 2Global Facial Recognition Market 2015-2019: Key Vendors are 3M Cogent, Cognitec Systems, NEC and Safran Group 3
... have found that melatonin, a naturally occurring brain substance, ... as seasonal affective disorder, or SAD. The study is ... National Academy of Science. , The study was led ... in the study of circadian (24-hour) rhythm disturbances, such ...
... and infects the most common and deadly form of brain ... devour themselves, researchers at The University of Texas M. D. ... the National Cancer Institute. , The modified adenovirus homed in ... among the cancer cells -- a process called autophagy -- ...
... the neural machinery that triggers the hungry brain to ... swings the other way after a hearty meal, as ... siesta. However, scientists have understood little about how the ... energy-related behaviors. , Now, in an article in the ...
Cached Biology News:Melatonin improves mood in winter depression 2Targeted virus compels cancer cells to eat themselves 2Targeted virus compels cancer cells to eat themselves 3New mechanism explains glucose effect on wakefulness 2New mechanism explains glucose effect on wakefulness 3
Request Info...
... Glucagon-like peptide-1(7-36) amide (GLP-1), C-terminal ... but shows <0.1% cross reactivity with ... or other related peptides such as ... Most mammalian species. GLP-1 is identical ...
Anti Human JAM-1, Monoclonal Antibody, Clone M.Ab.F11...
MOUSE ANTI HUMAN CYTOKERATIN 1-8...
Biology Products: